QS-21

Phase 2Biologic

Pfizer

QS-21 is one of 42 biologic programs targeting Pancreatic Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Pancreatic CancerActive, not recruiting

Pancreatic CancerPhase 2

Active, not recruiting

Competition

Competitive Landscape

307 competitors in Pancreatic Cancer

#DrugCompanyPhaseTrials

Medrol

Pfizer

Preclinical

1 2

Byetta

AstraZeneca

Preclinical

1 3

Ayvakit Sprinkle

MMemorial Sloan Kettering Cancer Center

Preclinical

1 4

Xylocaine

MMEDRx USA, Inc.

Preclinical

1 5

Feraheme

AAzurity Pharmaceuticals

Preclinical

1 6

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

1 7

Active Comparator

Moderna

Preclinical

1 8

QS-21

Pfizer

Phase 2

1 9

Secretin-Ferring

Ferring

Preclinical

1 10

Hyperpolarized 13c Pyruvate

UUniversity of Maryland, Baltimore

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Immunogenicity3 trials

A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled HIV-1 Vaccine Trial to Evaluate the Safety and Immunogenicity of MN Recombinant Soluble gp120/HIV-1 (rsgp120/HIV-1) (Genentech) in Combination With QS21 Adjuvant and/or Alum in Healthy Adults

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00001052·110 enrolled

A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled HIV-1 Vaccine Trial to Evaluate the Safety and Immunogenicity of rgp120/HIV-1MN (Genentech) in Combination With QS21 Adjuvant and/or Alum in Healthy Adults.

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00001044·80 enrolled

A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Immunogenicity of HIV-1 MN rsgp120 and Bivalent AIDSVAX B/E (HIV-1 MN rgp120/A244 rgp120) in Combination With QS-21 With or Without Alum in Healthy HIV-1 Uninfected Adults

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00001096·60 enrolled

Mild to Moderate Alzheimer's Disease2 trials

Study Evaluating Safety, Tolerability, And Immunogenicity Of ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease

Completed· Pfizer logo

Pfizer·Phase 2·NCT00479557·86 enrolled

Study Evaluating ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease

Completed· Pfizer logo

Pfizer·Phase 2·NCT00498602·160 enrolled

Effectiveness1 trial

Safety and Effectiveness of Two Different Formulations of an HIV Vaccine in Infants Born to HIV-Infected Women

Withdrawn·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00000809

Pancreatic Cancer1 trial

Tg01 Vaccine / Qs-21 Stimulon™ With Or Without Balstilimab As Maintenance Therapy Following Adjuvant Chemotherapy In Patients With Resected Pancreatic Cancer

Active, not recruiting·UUniversity of Kansas Medical Center·Phase 2·NCT05638698·24 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for QS-21. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — QS-21 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for QS-21. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Pfizer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: Pfizer

QS-21

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Immunogenicity3 trials

Mild to Moderate Alzheimer's Disease2 trials

Effectiveness1 trial

Pancreatic Cancer1 trial

References

Drug Info

Quick Facts

Related News